Discover

DMRA
Damora Therapeutics, Inc.
30.36
1 x 30.31
1 x 33.81
bid
ask
+
0.82
2.78%
1 @ 04:00 PM
30.36 +0.00 (0.00%)
Ytd31.94%
1y798.22%
29.14
day range
30.78
2.45
52 week range
38.33
Open29.89Prev Close29.54Low29.14High30.78Mkt Cap1.87B
Vol0.00Avg Vol585.31KEPS-8.82P/E-3.44Forward P/E-14.22
Beta1.48Short Ratio4.84Inst. Own102.22%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1150-d Avg26.52200-d Avg24.351yr Est44.67
Income Statement
Operating Expenses30.81M
Research and Development Expense23.78M
Selling, General and Administrative Expense7.03M
Operating Income-30.81M
Income Tax Expense42.00K
Net Income-27.78M
Net Income Common Stock-27.78M
Net Income Common Stock (USD)-27.78M
Consolidated Income-27.78M
Earnings per Basic Share-0.62
Earnings per Basic Share (USD)-0.62
Earnings per Diluted Share-0.62
Earning Before Interest & Taxes (EBIT)-27.74M
Earning Before Interest & Taxes (USD)-27.74M
Weighted Average Shares34.30M
Weighted Average Shares Diluted34.30M
Balance Sheet
Cash and Equivalents532.90M
Cash and Equivalents (USD)532.90M
Current Assets535.41M
Total Assets535.44M
Current Liabilities23.81M
Total Liabilities23.84M
Accumulated Retained Earnings (Deficit)-515.15M
Accumulated Other Comprehensive Income754.00K
Shareholders Equity511.60M
Shareholders Equity (USD)511.60M
Assets Non-Current34.00K
Liabilities Non-Current27.00K
Trade and Non-Trade Payables819.00K
Cash Flow
Depreciation, Amortization & Accretion68.00K
Net Cash Flow from Financing295.92M
Net Cash Flow / Change in Cash & Cash Equivalents275.32M
Issuance (Purchase) of Equity Shares295.92M
Net Cash Flow from Operations-20.60M
Effect of Exchange Rate Changes on Cash -48.00K
Share Based Compensation3.13M